Enhancing patient safety is our mission

The success of a drug and its benefit to the patient or consumer is determined in the market. Why not use intelligence from the real world to prepare for the launch and to monitor and optimise its success? PHOENIX group is a leading integrated healthcare provider present in 27 European countries. Our real-world universe includes 150,000,000 patient contacts each year visiting our 2,500 own pharmacies, one of our 13,500 cooperation partners or one of the 56,000 pharmacies which are supplied with products through the wholesale channel.

On 9th February 2019 the European Falsified Medicines Directive (FMD) is going into effect. The aim of FMD is to combat the entry of falsified medicines in the legitimate pharmaceutical supply chain. The FMD requires the placement of safety features consisting of a unique identifier and an anti-tampering device on the packaging of certain prescribed medicinal products for human use for the purposes of allowing their identification and authentication.

The PHOENIX group as trusted and quality-oriented healthcare provider in 27 European countries takes the topic of Falsified Medicines Directivevery seriously.Several business segments are impacted: retail, wholesale, healthcare logistics (pre-wholesale) and GMP services, such as repackaging. The implementation of FMD across the different business segments in the various countries is progressing well and PHOENIX will be ready and FMD-compliant by 9th February 2019.

Especially patient safety is of paramount importance to PHOENIX and that's why our engagement is an essential step forward to ensure the safety of medicines that reach patients - in every market! That's why we have been working diligently and pro-actively on the implementation of the EU Falsified Medicines Directive across all of our business areas to be fully compliant to the legislation in all impacted markets. PHOENIX is constantly involved in the implementation process together with the other supply chain panners and their representative bodies at both national and European levels. In this respect, PHOENIX has collaborated and still actively collaborating actively with the European Healthcare Distribution Association (GIRP), which functions as the umbrella organisation for pharmaceutical full line wholesalers in Europe, and of which PHOENIX is a full member company. 

In addition to the technological aspects of the FMD implementation, PHOENIX countries are investing a lot of effort locally in dispensing appropriate education and training to their employees, in order to make the transition into the FMD era as seamless as possible, which by extension, implies better service to our end customers, in line with our patient-centric approach.

Go to article: Home | Rise of The Tech GiantsGo to article: The Pharma Industry BriefingGo to article: EditorialGo to article: NSF Go to article: ContentsGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: NewsGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: DaiichiGo to article: Is China the next great hope for the pharma industry?Go to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Antimicrobial resistance: is pharmaceutical pollution creating superbugs?Go to article: MedelpharmGo to article: Why is it so hard to reproduce medical research resultsGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Pat-INFORMED: the solution to drug patent procurement issues?Go to article: TSS ABGo to article: Will tech giants like Amazon and Google change the pharma sector forever? Go to article: Capsugel Company InsightGo to article: CapsugelGo to article: Unreal Engine: from gaming to ground-breaking cures Go to article: QualiMetriXGo to article: Are pharma supply chains ready for the next major disruption?Go to article: SensitechGo to article: Can blockchain stem the tide of counterfeit drugs in India? Go to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: EventsGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Event: Outsourcing in Clinical Trials East Asia Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Event: Pharmpack EuropeGo to article: Next issueGo to article: PJC Company InsightGo to article: Corbion PuracGo to article: Abiogen PharmaGo to article: BEAGo to article: Unither PharmaceuticalsGo to article: EvolveGo to article: Cargolux Company InsightGo to article: CargoluxGo to article: LaudaGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: G.F.Go to article: Phoenix Company InsightGo to article: PhoenixGo to article: EcocoolGo to article: B Medical SystemsGo to article: B & W Tek Go to article: Miami International AirportGo to article: PharmasolGo to article: Cryo StoreGo to article: AlpexGo to article: AECO Telecom & Security Systems